E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic cough which continues without enough improvement after treatment for the disease(s) causing the cough, or as an unexplained cough, for which the disease has not been determined. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066656 |
E.1.2 | Term | Chronic cough |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo |
|
E.2.2 | Secondary objectives of the trial |
To compare the efficacy of S-600918 to that of placebo in patients with refractory chronic cough based on the following measurements: - Number of coughs per hour while awake - Number of coughs per hour while asleep - Severity of cough as assessed on the Visual Analog Scale (VAS) - Leicester Cough Questionnaire (LCQ) - International Consultation on Incontinence Modular Questionnaire-Short Form (ICIQ SF) - Short-Form (36) Health Survey (SF-36), version 2 - Patient Global Impression of Change (PGIC) To evaluate the safety of S-600918 in patients with refractory chronic cough. To assess the pharmacokinetics (PK) of S-600918 and its metabolite (S-600918 acyl glucuronide) in patients with refractory chronic cough. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Having refractory chronic cough (including unexplained chronic cough) for at least 1 year. - If female and of childbearing potential, agreement to use one of the allowed contraceptive methods. - Capable of giving signed informed consent. |
|
E.4 | Principal exclusion criteria |
- Currently smokes or uses potentially irritating inhalational agents (eg, e-cigarettes, smokeless cigarettes, vaping); stopped smoking or using potentially irritating inhalational agents within the last year; or has a smoking history of 20 pack-years or more. - Has chronic obstructive pulmonary disease or uncontrolled asthma. - Has a clinically unstable medical condition. - History of or ongoing significant psychiatric disorder. - History of respiratory tract infection or significant change in lung function or a pulmonary condition in the last 4 weeks. - History of malignancy in the last 5 years. - History of severe drug allergy. - History of alcohol or drug abuse in the last year or currently uses any form of marijuana or illicit drugs. - Has a clinically significant finding on a chest x-ray or chest computed tomography (CT) scan in the last year. - Has systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg. - Received S-600918 previously. - Received an investigational drug in the last 3 months. - Received an angiotensin converting enzyme (ACE) inhibitor in the last 3 months or requires such treatment. - Has a positive serologic test for human immunodeficiency virus (HIV) antigen or antibody, hepatitis B virus surface antigen, or hepatitis C virus ribonucleic acid (RNA). - If female, pregnant or trying to become pregnant or breastfeeding. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the ratio of the number of coughs per hour in 24 hours (based on cough counts recorded by the cough monitor) after administration of study drug for 4 weeks to that at baseline. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•A reduction from baseline in the number of coughs per hour in 24 hours by ≥30%, ≥50%, and ≥70% • The ratio of the number of coughs per hour while awake after administration of study drug for 4 weeks to that at baseline and a reduction by ≥30%, ≥50%, and ≥70% • The ratio of the number of coughs per hour while asleep after administration of study drug for 4 weeks to that at baseline • The change from baseline in weekly cough severity as assessed on the VAS (electronic tablet) • The change from baseline through Day 7 in daily cough severity as assessed on the VAS (eDiary) • The change in LCQ and achievement of an increase (ie, improvement) of ≥1.3 points • The change in ICIQ-SF • The change in SF-36 • PGIC |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Czech Republic |
Japan |
Poland |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |